ChiCTR2600125790 版本V1.0 版本创建时间2026/06/01 01:47:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600125790 

最近更新日期:

Date of Last Refreshed on:

2026-06-01 01:47:09 

注册时间:

Date of Registration:

2026-06-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

慢性萎缩性胃炎背景下反流性食管炎的反流特征与食管动力学分析:基于HRM与MII-pH的病例对照研究

Public title:

Reflux Characteristics and Esophageal Motility in Reflux Esophagitis with Chronic Atrophic Gastritis: A Case-Control Study Based on HRM and MII-pH

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性萎缩性胃炎背景下反流性食管炎的反流特征与食管动力学分析:基于HRM与MII-pH的病例对照研究

Scientific title:

Reflux Characteristics and Esophageal Motility in Reflux Esophagitis with Chronic Atrophic Gastritis: A Case-Control Study Based on HRM and MII-pH

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周语诗 

研究负责人:

周语诗 

Applicant:

Yushi Zhou 

Study leader:

Yushi Zhou 

申请注册联系人电话:

Applicant telephone:

+86 858 832 1422

研究负责人电话:

Study leader's
telephone:

+86 858 832 1422

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yushizhou0428@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

yushizhou0428@gmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

贵州省六盘水市钟山区钟山西路308号

研究负责人通讯地址:

贵州省六盘水市钟山区钟山西路308号

Applicant address:

No. 308, Zhongshan West Road, Zhongshan District, Liupanshui City, Guizhou Province

Study leader's address:

No. 308, Zhongshan West Road, Zhongshan District, Liupanshui City, Guizhou Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

六盘水市人民医院

Applicant's institution:

Liupanshui People's Hospital

研究负责人所在单位:

六盘水市人民医院

Affiliation of the Leader:

Liupanshui People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LPSSYY-2026-05

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

六盘水市人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Liupanshui People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-03-07 00:00:00

伦理委员会联系人:

刘理燕

Contact Name of the ethic committee:

Liyan Liu

伦理委员会联系地址:

贵州省六盘水市钟山区钟山西路308号

Contact Address of the ethic committee:

No. 308, Zhongshan West Road, Zhongshan District, Liupanshui City, Guizhou Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 199 8560 1180

伦理委员会联系人邮箱:

Contact email of the ethic committee:

2925472051@qq.com

研究实施负责(组长)单位:

六盘水市人民医院

Primary sponsor:

Liupanshui People's Hospital

研究实施负责(组长)单位地址:

贵州省六盘水市钟山区钟山西路308号

Primary sponsor's address:

No. 308, Zhongshan West Road, Zhongshan District, Liupanshui City, Guizhou Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

贵州省

市(区县):

六盘水市

Country:

China

Province:

Guizhou

City:

Liupanshui

单位(医院):

六盘水市人民医院

具体地址:

贵州省六盘水市钟山区钟山西路308号

Institution
hospital:

Liupanshui People's Hospital

Address:

No. 308, Zhongshan West Road, Zhongshan District, Liupanshui City, Guizhou Province

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

研究疾病:

反流性食管炎  

Target disease:

Reflux Esophagitis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

比较慢性萎缩性胃炎合并反流性食管炎患者(CAG+RE)与无萎缩性胃炎的反流性食管炎患者(non-CAG+RE)之间的反流特征及食管动力学差异,并探索 CAG 背景下 RE 的潜在反流机制表型。  

Objectives of Study:

To compare reflux characteristics and esophageal motility between CAG+RE and non-CAG+RE patients, and to investigate the potential reflux mechanism phenotypes underlying RE in the setting of chronic atrophic gastritis.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄18–75岁,男女不限; 2.半年内胃镜证实LA A/B/C/D级反流性食管炎(洛杉矶LA分级); 3.同意完成HRM与MII-pH检测及问卷采集; 4.同意参与前瞻性随访和数据采集,并签署知情同意

Inclusion criteria

1. Age: 18 - 75 years old, gender not restricted; 2. Within the past six months, confirmed by gastroscopy as LA A/B/C/D grade reflux esophagitis (Los Angeles LA classification); 3. Agree to complete HRM and MII-pH tests as well as questionnaire collection; 4. Agree to participate in the prospective follow-up and data collection, and sign the informed consent form.

排除标准:

若受试者存在以下任一情况,将予以排除: 1.特殊类型胃炎(自身免疫胃炎/化学性/胆汁反流性萎缩性胃炎); 2.存在任何其余食管结构性或黏膜疾病(如 Barrett 食管、嗜酸性食管炎、食管狭窄、食管静脉曲张、恶性肿瘤,或既往化学性 / 热损伤 / 放射损伤史); 3.存在影响食管-胃肠动力的系统性疾病(如系统性硬化症、皮肌炎、系统性红斑狼疮、淀粉样变性),未控制的糖尿病(空腹血糖 >=11.1 mmol/L),严重肺心脑血管疾病,明显肝肾功能障碍或严重精神疾病; 4.既往胃或食管手术史(含 EMR/ESD); 5.妊娠期、哺乳期或计划在研究期间妊娠者; 6.近 4 周内接受根除治疗或影响动力/反流的药物未按停药要求洗脱

Exclusion criteria:

If the subject has any of the following conditions, they will be excluded: 1. Special types of gastritis (autoimmune gastritis/chemical/choledocholitic atrophic gastritis); 2. Any other structural or mucosal diseases of the esophagus (such as Barrett's esophagus, eosinophilic esophagitis, esophageal stenosis, esophageal varices, malignant tumors, or a history of chemical/thermal/radiation injury); 3. Systemic diseases that affect esophageal-gastrointestinal motility (such as systemic sclerosis, dermatomyositis, systemic lupus erythematosus, amyloidosis), uncontrolled diabetes (fasting blood glucose >= 11.1 mmol/L), severe pulmonary, cardiovascular or cerebrovascular diseases, obvious liver and kidney dysfunction or severe mental illness; 4. Previous history of gastric or esophageal surgery (including EMR/ESD); 5. Pregnant, lactating or planning to become pregnant during the study period; 6. Within the past 4 weeks, received eradication treatment or drugs that affect motility/ reflux and failed to follow the withdrawal requirements.

研究实施时间:

Study execute time:

From 2026-05-20 00:00:00 To 2027-05-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2027-04-30 00:00:00

干预措施:

Interventions:

组别:

慢性萎缩性胃炎+反流性食管炎观察组

样本量:

30

Group:

Chronic atrophic gastritis + reflux esophagitis observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

非慢性萎缩性胃炎+反流性食管炎观察组

样本量:

30

Group:

Observation group of non-chronic atrophic gastritis + reflux esophagitis

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

贵州省 

市(区县):

六盘水市 

Country:

China

Province:

Guizhou

City:

Liupanshui

单位(医院):

六盘水市人民医院 

单位级别:

三甲 

Institution
hospital:

Liupanshui People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

非酸反流事件比例

指标类型:

主要指标

Outcome:

Proportion of non-acid reflux events

Type:

Primary indicator

测量时间点:

入组后4周内完成HRM及24h MII-pH检查

测量方法:

24小时多通道腔内阻抗-pH监测(MII-pH)

Measure time point of outcome:

Complete HRM and 24-hour MII-pH monitoring within 4 weeks after enrollment.

Measure method:

24-hour multichannel intraluminal impedance-pH monitoring

指标中文名:

食管酸暴露时间

指标类型:

次要指标

Outcome:

Acid exposure time (AET)

Type:

Secondary indicator

测量时间点:

入组后4周内完成HRM及24h MII-pH检查

测量方法:

24小时多通道腔内阻抗-pH监测(MII-pH)

Measure time point of outcome:

Complete HRM and 24-hour MII-pH monitoring within 4 weeks after enrollment.

Measure method:

24-hour multichannel intraluminal impedance-pH monitoring

指标中文名:

反流事件总数

指标类型:

次要指标

Outcome:

Total reflux events

Type:

Secondary indicator

测量时间点:

入组后4周内完成HRM及24h MII-pH检查

测量方法:

24小时多通道腔内阻抗-pH监测(MII-pH)

Measure time point of outcome:

Complete HRM and 24-hour MII-pH monitoring within 4 weeks after enrollment.

Measure method:

24-hour multichannel intraluminal impedance-pH monitoring

指标中文名:

下食管括约肌压力

指标类型:

次要指标

Outcome:

Lower esophageal sphincter pressure (LES pressure)

Type:

Secondary indicator

测量时间点:

入组后4周内完成HRM及24h MII-pH检查

测量方法:

高分辨率食管测压(HRM)

Measure time point of outcome:

Complete HRM and 24-hour MII-pH monitoring within 4 weeks after enrollment.

Measure method:

High-resolution esophageal manometry

指标中文名:

无效食管蠕动比例

指标类型:

次要指标

Outcome:

Proportion of ineffective esophageal motility (IEM)

Type:

Secondary indicator

测量时间点:

入组后4周内完成HRM及24h MII-pH检查

测量方法:

高分辨率食管测压(HRM)

Measure time point of outcome:

Complete HRM and 24-hour MII-pH monitoring within 4 weeks after enrollment.

Measure method:

High-resolution esophageal manometry

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-06-01 01:47:09